MX2023014420A - Metodos para tratar el cancer de mama. - Google Patents
Metodos para tratar el cancer de mama.Info
- Publication number
- MX2023014420A MX2023014420A MX2023014420A MX2023014420A MX2023014420A MX 2023014420 A MX2023014420 A MX 2023014420A MX 2023014420 A MX2023014420 A MX 2023014420A MX 2023014420 A MX2023014420 A MX 2023014420A MX 2023014420 A MX2023014420 A MX 2023014420A
- Authority
- MX
- Mexico
- Prior art keywords
- breast cancer
- methods
- treating breast
- subject
- adjuvant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163195795P | 2021-06-02 | 2021-06-02 | |
| PCT/EP2022/064697 WO2022253800A1 (en) | 2021-06-02 | 2022-05-31 | Methods of treating breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014420A true MX2023014420A (es) | 2024-04-23 |
Family
ID=82117716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014420A MX2023014420A (es) | 2021-06-02 | 2022-05-31 | Metodos para tratar el cancer de mama. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240269135A1 (https=) |
| EP (1) | EP4346828A1 (https=) |
| JP (1) | JP2024520142A (https=) |
| KR (1) | KR20240016344A (https=) |
| CN (1) | CN118139624A (https=) |
| AU (1) | AU2022286616A1 (https=) |
| BR (1) | BR112023025003A2 (https=) |
| CA (1) | CA3220751A1 (https=) |
| CL (1) | CL2023003533A1 (https=) |
| IL (1) | IL308684A (https=) |
| MX (1) | MX2023014420A (https=) |
| WO (1) | WO2022253800A1 (https=) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1633724T3 (pl) | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
-
2022
- 2022-05-31 CA CA3220751A patent/CA3220751A1/en active Pending
- 2022-05-31 US US18/564,778 patent/US20240269135A1/en active Pending
- 2022-05-31 EP EP22732066.0A patent/EP4346828A1/en not_active Withdrawn
- 2022-05-31 KR KR1020237045312A patent/KR20240016344A/ko not_active Withdrawn
- 2022-05-31 MX MX2023014420A patent/MX2023014420A/es unknown
- 2022-05-31 JP JP2023574549A patent/JP2024520142A/ja not_active Withdrawn
- 2022-05-31 WO PCT/EP2022/064697 patent/WO2022253800A1/en not_active Ceased
- 2022-05-31 CN CN202280039309.4A patent/CN118139624A/zh active Pending
- 2022-05-31 BR BR112023025003A patent/BR112023025003A2/pt not_active Application Discontinuation
- 2022-05-31 IL IL308684A patent/IL308684A/en unknown
- 2022-05-31 AU AU2022286616A patent/AU2022286616A1/en not_active Abandoned
-
2023
- 2023-11-28 CL CL2023003533A patent/CL2023003533A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024520142A (ja) | 2024-05-21 |
| CA3220751A1 (en) | 2022-12-08 |
| CN118139624A (zh) | 2024-06-04 |
| WO2022253800A1 (en) | 2022-12-08 |
| US20240269135A1 (en) | 2024-08-15 |
| KR20240016344A (ko) | 2024-02-06 |
| BR112023025003A2 (pt) | 2024-02-20 |
| AU2022286616A1 (en) | 2024-01-18 |
| IL308684A (en) | 2024-01-01 |
| EP4346828A1 (en) | 2024-04-10 |
| CL2023003533A1 (es) | 2024-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4303583A3 (en) | Methods of treating disorders using csf1r inhibitors cross-reference to related applications | |
| ZA202100485B (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
| PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
| PH12019501119A1 (en) | Pharmaceutical composition for preventing or treating breast cancer including crystalline polymorph of tetraarsenic hexoxide, and method for producing same | |
| PH12021551047A1 (en) | Anti-ptk7 immune cell cancer therapy | |
| ZA201607488B (en) | Compounds for treating brain cancer | |
| MX2022000853A (es) | Anticuerpos anti-liv1 humanizados para el tratamiento de cancer. | |
| UY38360A (es) | Métodos de tratamiento del cáncer | |
| AU2015249633A8 (en) | Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab | |
| WO2020055643A3 (en) | Compounds, compositions and methods for treating or preventing her-driven cancers | |
| MX2022008099A (es) | Tratamiento para el cancer con inhibidores de cdk12/13. | |
| JOP20190073B1 (ar) | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 | |
| MA40075A (fr) | Combinaisons pour traiter des cancers | |
| MX2020012291A (es) | Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario. | |
| MX2025003936A (es) | Combinacion de talazoparib y enzalutamida en el tratamiento del cancer de prostata metastasico resistente a la castracion | |
| PH12022551081A1 (en) | Cancer treatments targeting cancer stem cells | |
| EP4442815A3 (en) | Compositions and methods for treating egfr positive cancers | |
| MX2024007260A (es) | Uso de terapia de combinacion para tratar el cancer. | |
| PH12021551657A1 (en) | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer | |
| MX2025007378A (es) | Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2 | |
| WO2022036065A3 (en) | Compositions and methods for treating cancers | |
| MX2022013557A (es) | Tratamiento combinado con anticuerpo anti-cd40 contra el cáncer. | |
| MX2023014420A (es) | Metodos para tratar el cancer de mama. | |
| MX2022004699A (es) | Metodos de tratamiento del cancer de mama con sobreexpresion de her2 con tucatinib en combinacion con capecitabina y trastuzumab. | |
| MX2021002884A (es) | Terapia de combinacion para el tratamiento de cancer de prostata. |